Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harald Hofer

Showing results (41-50 of 71) with videos related to

Pageof 8
Sort By:
Hepatology (Baltimore, Md.)|October 19, 2011
Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirinThomas-Matthias Scherzer, Albert Friedrich Stättermayer, Michael Strasser, et al.
Journal of Hepatology|May 29, 2012
Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis CAlbert Friedrich Stättermayer, Karoline Rutter, Sandra Beinhardt, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 5, 2003
Impact of high-dose interferon induction and ribavirin therapy in patients with chronic hepatitis C relapsing after or not responding to interferon monotherapyPetra Steindl-Munda, Peter Ferenci, Harald Brunner, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 1, 2013
Long-term outcomes of patients with Wilson disease in a large Austrian cohortSandra Beinhardt, Waltraud Leiss, Albert Friedrich Stättermayer, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 3, 2017
Long-term follow-up of ribavirin-free DAA-based treatment in HCV recurrence after orthotopic liver transplantationSandra Beinhardt, Ramona Al-Zoairy, Karin Kozbial, et al.
Journal of Hepatology|July 16, 2013
Effect of gender and ITPA polymorphisms on ribavirin-induced anemia in chronic hepatitis C patientsThomas-Matthias Scherzer, Albert Friedrich Stättermayer, Rudolf Stauber, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 26, 2017
Ultra-high-field magnetic resonance spectroscopy in non-alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non-alcoholic steatohepatitis and advanced fibrosisStefan Traussnigg, Christian Kienbacher, Martin Gajdošík, et al.
Hepatology (Baltimore, Md.)|May 6, 2008
A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3Peter Ferenci, Harald Brunner, Hermann Laferl, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 2, 2016
von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapyKaroline Rutter, Alexandra Etschmaier, Monika Ferlitsch, et al.
Digestive Diseases (Basel, Switzerland)|June 6, 2015
Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic DisordersMichael Trauner, Emina Halilbasic, Thierry Claudel, et al.
Pageof 8

Showing results (41-50 of 71) with videos related to

Sort By:
Pageof 8
Hepatology (Baltimore, Md.)|October 19, 2011
Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirinThomas-Matthias Scherzer, Albert Friedrich Stättermayer, Michael Strasser, et al.
Journal of Hepatology|May 29, 2012
Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis CAlbert Friedrich Stättermayer, Karoline Rutter, Sandra Beinhardt, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 5, 2003
Impact of high-dose interferon induction and ribavirin therapy in patients with chronic hepatitis C relapsing after or not responding to interferon monotherapyPetra Steindl-Munda, Peter Ferenci, Harald Brunner, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 1, 2013
Long-term outcomes of patients with Wilson disease in a large Austrian cohortSandra Beinhardt, Waltraud Leiss, Albert Friedrich Stättermayer, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 3, 2017
Long-term follow-up of ribavirin-free DAA-based treatment in HCV recurrence after orthotopic liver transplantationSandra Beinhardt, Ramona Al-Zoairy, Karin Kozbial, et al.
Journal of Hepatology|July 16, 2013
Effect of gender and ITPA polymorphisms on ribavirin-induced anemia in chronic hepatitis C patientsThomas-Matthias Scherzer, Albert Friedrich Stättermayer, Rudolf Stauber, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 26, 2017
Ultra-high-field magnetic resonance spectroscopy in non-alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non-alcoholic steatohepatitis and advanced fibrosisStefan Traussnigg, Christian Kienbacher, Martin Gajdošík, et al.
Hepatology (Baltimore, Md.)|May 6, 2008
A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3Peter Ferenci, Harald Brunner, Hermann Laferl, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 2, 2016
von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapyKaroline Rutter, Alexandra Etschmaier, Monika Ferlitsch, et al.
Digestive Diseases (Basel, Switzerland)|June 6, 2015
Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic DisordersMichael Trauner, Emina Halilbasic, Thierry Claudel, et al.
Pageof 8